

CLEARBRIDGE HEALTH LIMITED
(the "**Company**")
(Company Registration Number: 201001436C)
(Incorporated in the Republic of Singapore)

GRANT OF WAIVERS FROM RULES 705(1) AND 707(1) OF THE CATALIST RULES

1. The Board of Directors (the "**Board**") of the Company (together with its subsidiaries, the "**Group**") refers to the Company's announcements dated 1 March 2023 and 20 March 2023 relating to, among others, its application (the "**Waiver Application**") to the Singapore Exchange Securities Trading Limited ("**SGX-ST**") for waivers from Rules 705(1) and 707(1) of the Listing Manual Section B: Rules of Catalist of the SGX-ST ("**Catalist Rules**").
2. The Board also refers to the Company's announcement dated 6 April 2023 relating to the grant of approval by the Accounting, Corporate and Regulatory Authority ("**ACRA**") which the Company was informed of on 5 April 2023 in relation to the Company's concurrent application to ACRA on 20 March 2023 for:
 - (a) a 60-day extension pursuant to Section 175 of the Companies Act 1967 of Singapore ("**Companies Act**"), to hold the annual general meeting ("**AGM**") of the Company in relation to the financial year ended 31 December 2022 ("**FY2022**"), and to lay the audited financial statements of the Company in relation to FY2022 (the "**FY2022 Audited Financial Statements**") before the Company at the AGM by 29 June 2023; and
 - (b) a 60-day extension pursuant to Section 197 of the Companies Act, to lodge the annual return of the Company in relation to FY2022 by 30 July 2023.
3. Under the Catalist Rules:
 - (a) Rule 705(1) requires the Company to announce its unaudited full year financial statements of the Group (the "**FY2022 Unaudited Financial Statements**") for the financial year ended 31 December 2022 ("**FY2022**") by no later than 1 March 2023; and
 - (b) Rule 707(1) requires the AGM of the Company (the "**FY2022 AGM**") in relation to FY2022 to be held no later than 30 April 2023.
4. The Board wishes to announce that the Company had on 28 April 2023 received the SGX-ST's no objection in relation to the Waiver Application for:
 - (a) a three-month extension of the deadline under Rule 705(1) of the Catalist Rules to announce the FY2022 Unaudited Financial Statements by 31 May 2023; and
 - (b) a 60-day extension of the deadline under Rule 707(1) of the Catalist Rules, to hold the FY2022 AGM by 29 June 2023,

(collectively, the "**Waiver Grants**").

5. The Waiver Grants are subject to the following conditions:
- (a) the Company announcing the Waiver Grants, the reasons for making the Waiver Application, the conditions as required under Rule 106 of the Catalist Rules and if the conditions of the Waiver Grants have been satisfied. If the conditions of the Waiver Grants have not been met on the date of the announcement, the Company must make an update announcement when the conditions have all been met;
 - (b) submission of a written confirmation from the Company that it is not aware of any information that will have a material bearing on investors' decision which has yet to be announced by the Company in relation to the Waiver Grants; and
 - (c) submission of a written confirmation by the Board that the Waiver Grants will not be in contravention of any laws and regulations governing the Company and the constitution of the Company (the "**Constitution**"),

(collectively, the "**Conditions**").

6. As previously announced in the Company's announcement of 20 March 2023, the Company had sought the Waiver Grants from the SGX-ST because, as of the date of the Waiver Application and as of the date of this announcement, the Company has not been able to finalise its FY2022 Unaudited Financial Statements as it is pending access by Lunadorii Inc. ("**Lunadorii**") to the necessary financial information of PT Tirta Medika Jaya ("**TMJ**") and PT Indo Genesis Medika ("**IGM**"). TMJ and IGM were both previously indirect subsidiaries of the Company prior to the Company's disposal of 100% of its shareholding interests in Clearbridge Medical Asia Pte. Ltd. and SAM Laboratory Pte. Ltd. to Lunadorii on 7 October 2022 (the "**Disposal**") which hold TMJ and IGM, respectively. Lunadorii had also informed the Company that it has not been able to access the necessary financial information of TMJ and IGM in a timely manner for the purpose of finalising the Company's FY2022 Unaudited Financial Statements and requires more time to do so because at the time of completion of the Disposal on 7 October 2022, the management accounts of TMJ and IGM for the financial period commencing 1 July 2022 to 30 September 2022, and up until the date of the Disposal on 7 October 2022 were not yet available. Since the Disposal on 7 October 2022, the Company has had difficulty accessing the necessary financial information through Lunadorii due to the lack of cooperation from the staff of TMJ and IGM during the related transition process.
7. As of the date of this announcement, the Conditions have all been met, save that the Company will be in breach of Regulation 56(1) of the Constitution as expressly stated in the Waiver Application on 20 March 2023. Regulation 56(1) of the Constitution provides, among others, that the Company shall in each year hold an AGM, and not more than 15 months shall elapse between the date of one AGM and that of the next. Regulation 56(1) also provides that the interval between the close of a financial year of the Company and the date of the Company's AGM shall not exceed four months. The last AGM of the Company was held on 26 April 2022. Accordingly, given that the Waiver Grants will permit the FY2022 AGM to be held by 29 June 2023, the Company will be in breach of Regulation 56(1). As further stated in the Waiver

Application, although the Company will be in breach of its Constitution, the Company is of the view that in these circumstances, the Company had no option reasonably available but to make the Waiver Application, and the non-compliance with the Constitution in this case has no material impact on the Company. It is noted in the Waiver Grants that the SGX-ST had provided its no objection to the Waiver Application on the basis of the Company's submissions and representations to the SGX-ST, including the breach of Regulation 56(1) of the Constitution as stated in the Waiver Application. Accordingly, the Board has submitted the written confirmation to the SGX-ST in satisfaction of the Condition in paragraph 5(c) above on this basis.

8. Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants, or other professional advisers if they are in doubt about the actions that they should take.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Executive Director and Chief Executive Officer

30 April 2023

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Catalist Rules. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*